Who are Questran Light's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Welchol, Colestid, colesevelam HCl, "cholestagel®" (Colesevelam), high bile acid binding blenderized diet, Cholestyramine Powder.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cholestyramine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Questran Light — Competitive Intelligence Brief

Questran Light (CHOLESTYRAMINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bile Acid Sequestrant [EPC]. Area: Metabolic.

marketed Bile Acid Sequestrant [EPC] Metabolic Live · refreshed every 30 min

Target snapshot

Questran Light (CHOLESTYRAMINE) — Bristol Myers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Questran Light TARGET	CHOLESTYRAMINE	Bristol Myers	marketed	Bile Acid Sequestrant [EPC]		1973-01-01
Welchol	COLESEVELAM	Cosette	marketed	Bile Acid Sequestrant		2000-01-01
Colestid	Colestipol	Pfizer	marketed	Bile Acid Sequestrant		1977-01-01
colesevelam HCl	colesevelam HCl	HealthPartners Institute	marketed	Bile acid sequestrant	Bile acids
"cholestagel®" (Colesevelam)	"cholestagel®" (Colesevelam)	University Hospital, Gentofte, Copenhagen	marketed	Bile acid sequestrant	Bile acids
high bile acid binding blenderized diet	high bile acid binding blenderized diet	Boston Children's Hospital	marketed	Dietary intervention / Bile acid sequestrant
Cholestyramine Powder	Cholestyramine Powder	Centre Hospitalier Universitaire de Nice	marketed	Bile acid sequestrant	Bile acids

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bile Acid Sequestrant [EPC] class)

Bristol Myers · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Questran Light — Competitive Intelligence Brief. https://druglandscape.com/ci/cholestyramine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab